This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter performance is likely to reflect growth in its six global business units.
Stryker (SYK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings likely to reflect strong segmental performances by Medsurg and Neurotechnology & Spine.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Haemonetics (HAE) Buys enicor to Expand Testing Portfolio
by Zacks Equity Research
Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.
Medtronic's Evolut TAVR System Shows Positive Study Results
by Zacks Equity Research
Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.
Haemonetics (HAE) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allscripts' Veradigm Business Line Unveils New Solution
by Zacks Equity Research
Allscripts' (MDRX) Veradigm business line introduces new solution that will drive growing medication adherence and improve patient care.
Why Is Haemonetics (HAE) Down 8.4% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Haemonetics (HAE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here's Why You Should Retain Haemonetics in Your Portfolio Now
by Zacks Equity Research
Haemonetics (HAE) witnesses high investor confidence on solid prospects.
Here's Why You Should Add Hill-Rom to Your Portfolio Now
by Zacks Equity Research
Investor confidence is at a high, thanks to Hill-Rom (HRC) solid prospects.
Has Haemonetics (HAE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (HAE) Outperforming Other Medical Stocks This Year?
Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand
by Zacks Equity Research
Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.
Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 23.68% and 2.29%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Alliances Aid Quest Diagnostics Despite Reimbursement Woes
by Urmimala Biswas
Quest Diagnostics (DGX) is currently concentrating on diagnostic information services arm and disciplined capital deployment.
New Product Suite Boosts Intersect ENT Despite Cost Concerns
by Zacks Equity Research
With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.
Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
by Zacks Equity Research
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
Zimmer Biomet Rides on Product Launches Despite Pricing Woes
by Zacks Equity Research
Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.
Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block
by Zacks Equity Research
Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.
Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu
by Zacks Equity Research
Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.
ResMed Launches AirFit F30i CPAP Mask, Widens Client Base
by Zacks Equity Research
ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.
Here's Why You Should Retain Edwards Lifesciences Stock Now
by Zacks Equity Research
Investors can hold on to Edwards Lifesciences (EW) in their portfolio for now, thanks to solid prospects.